360b / Shutterstock.com
Bayer has lost an attempt to block a generic version of its cancer drug Nexavar (Sorafenib) in India after the country’s highest court rejected an appeal from the German pharmaceutical company.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bayer, Nexavar, Supreme Court of India, Natco Pharma, compulsory licence
